Appropriate diabetes self-management is essential to achieving optimal clinical outcomes. The Patient Activation Measure (PAM) is a validated, 100-item questionnaire that assesses patient activation (scored: 0=low, 100=high) and reveals four levels of activation relevant to diabetes self-management: Level 1 - disengaged and overwhelmed; Level 2 - becoming aware but still struggling; Level 3 - taking action and gaining control; and Level 4 - maintaining behaviors and pushing forward. This 12-month, observational, self-controlled multi-site study combined retrospective (6 months pre-baseline) and prospective (6 months post-baseline) to assess the impact of the Diabetes Health Partnership (DHP) program, a telephonic coaching program, on patient activation among 57 suboptimally controlled at baseline (8.4±1.1% A1C). Mean PAM total scores increased from 61.8±12.1 at baseline to 71.3±12.7 at study endpoint (p<0.0001). The downward shift in Level 1 and upward shift in Level 4 were most notable. (Figure 1) Significant increases in participant confidence in managing their diabetes (p<0.0001) and in having a clear plan for self-management (p=0.0004) were observed. Participation in the DHP program was associated with increased activation and greater confidence in participants’ ability to manage their diabetes.


A. Buskirk: Employee; Self; Roche Diabetes Care. W.C. Biggs: Consultant; Self; Roche Diabetes Care. Research Support; Self; Dexcom, Inc., Gan & Lee Pharmaceuticals, Mylan, Novo Nordisk A/S, Sanofi US. L. Borsa: None. M.R. Lyden: None. C. Parkin: Consultant; Self; Abbott, CeQur Corporation, Dexcom, Inc., DreaMed Diabetes, Novo Nordisk Inc., Onduo, Roche Diabetes Care, Valeritas, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at